52
Participants
Start Date
April 30, 2004
Primary Completion Date
June 30, 2005
Study Completion Date
April 30, 2008
Sorafenib (Nexavar, BAY43-9006)
BAY43-9006 400 mg bid X 28 day cycles \[Continuous treatment for a maximum of 2 years; potential for compassionate use and long term survival follow-up post drug discontinuation.
Großhansdorf
Houston